Revenue grew 17% and non-GAAP EPS rose 11% year-over-year, driven by record sales of Dupixent, EYLEA HD, and Libtayo. The pipeline remains robust with multiple regulatory milestones ahead, and capital allocation continues to prioritize internal R&D and disciplined external opportunities.

Based on

This is an AI-generated summary and may contain inaccuracies. Please verify any important information with the original source.